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JC virus (JCV) causes progressive multifocal leukoencephalopathy (PML) in immunocompromised patients.
The mechanism of JCV reactivation and immunity in a transplanted immune system remains unclear. We
prospectively studied 30 patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) and
collected blood and urine samples before HSCT and 3, 6, and 12 to 18 months after HSCT. Before HSCT, JCV
DNA was detected in 7 of 30 urine, 5 of 30 peripheral blood mononuclear cells (PBMC) and 6 of 30 plasma
samples. Although JC viruria remained stable after HSCT with detection in 5 of 21 samples, viremia was
detected in only 1 of 22 plasma and none of 22 PBMC samples 12 to 18 months after HSCT. Prevalence of anti-
JCV IgG was 83% before HSCT and decreased to 72% at 12 to 18 months. Anti-JCV IgM was rarely detected. JCV-
speciﬁc CD4þ and CD8þ T cell responses increased 12 to 18 months after HSCT. Although JC viruria correlated
directly with detection of anti-JCV IgG, the cellular immune response to JCV measured by ELISpot was
inversely correlated with anti-JCV IgG response. The diagnosis of acute myelogenous leukemia and age group
were 2 independent patient factors associated with signiﬁcantly reduced cellular immune responses to JCV.
This prospective study in HSCT patients provides a model of interactions between the host immune response
and viral activation in multiple compartments during the recovery of the immune system.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
JC virus (JCV) causes progressive multifocal leukoence-
phalopathy (PML) in immunocompromised patients [1,2]. Up
to 80% of the general populations is seropositive for JCV and
both the humoral and cellular immune responses are
necessary for containment of viral proliferation [3,4]. Thus,
immunocompromised patients, including those with hema-
tological malignancies requiring allogeneic hematopoietic
stem cell transplantation (HSCT), are at increased risk for
developing PML. Indeed, PML was initially described in
3 patients with hematological malignancies in 1958 [5].
Currently, many more patients survive HSCT because of, inedgments on page 998.
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they receive after transplantation. Among all published re-
ports of transplant recipients with PML, HSCT patients make
up the largest group; up to 8% of PML patients have hema-
tological cancers [6,7]. The incidence rate of PML in patients
with HSCT was estimated at 35.4 in 100,000 person-years
[8]. Furthermore, PML can develop as early as 1.5 months
or as late as years after transplantation and is associated with
themyeloablative conditioning regimen used towipe out the
HSCT recipient cells in preparation for transplantation [7,9].
The median survival time for HSCT recipient with PML is less
than 2 years [7]. Thus, PML is devastating in HSCT patients as
there is no effective therapy for this disease.
Although studies have examined the host immune re-
sponses to JCV in patients with PML, little is known of the
host-viral interactions before PML onset [10-12]. Of impor-
tance, a better understanding of how the host immune re-
sponses control viral proliferation is crucial to preventing the
development of PML. Even though the cellular immune sys-
tem cannot eradicate chronic viruses, immune surveillance
prevents active infection under normal immune conditions.Transplantation.
Table 1
Study Subjects Characteristics
Characteristic n
Indication for transplantation
Acute myelogenous leukemia 13
Multiple myeloma 6
Chronic lymphoid leukemia 3
Chronic myeloid leukemia 2
Non Hodgkin’s lymphoma 2
Acute lymphoid leukemia 1
Others 3
Gender
Male 20
Female 10
Types of transplantation
Matched unrelated donor 13
Matched related donor 11
Umbilical cord blood 6
Conditioning regimens
Myeloablative 22
Reduced intensity 8
GVHD
GVHD during study period 11
No GVHD during study period 19
Concurrent viremia*
Viremia during study period 11
No viremia during study period 19
GVHD indicates graft-versus-host disease.
* Study subjects with diagnosis of another viral infection during
the study period, including herpes simplex, Epstein Barr virus,
cytomegalovirus, and parainﬂuenza.
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complication after HSCT [13]. It is unclear when JCV reac-
tivation occurs or, in HSCT, how the transplanted immune
system interactswith JCV in the infected host tomaintain viral
latency. Thus,we designed a prospective study to analyze host
immune responses to JCV before HSCT and to examine the
dynamic changes as the transplanted immune system re-
constitutes and expands its antiviral armamentarium.
METHODS
Study Subjects and Samples
This study was approved by the Dana Farber Harvard Cancer Center
Institutional Review Board. Adult patients were enrolled consecutively from
April 2008 to July 2010 as they presented for allogeneic HSCT at Beth Israel
Deaconess Medical Center. Thirty healthy volunteers were also enrolled. All
subjects consented to the study. Blood and urine samples were obtained
before HSCT and 3 months, 6 months, and 12 to 18 months after HSCT.
Plasma and peripheral blood mononuclear cells (PBMC) were isolated as
previously reported [12]. Aliquots of PBMC, plasma, and urinewere stored at
-80C for DNA extraction.
DNA Extraction and Quantitative PCR for JCV
Total DNA was extracted from PBMC using the QIAamp DNA Blood Mini
Kit (Qiagen, Valencia, CA) and from plasma and urine samples using the
QiagenMinElute kit, following themanufacturers’ instructions. JCV DNAwas
detected and quantiﬁed by quantitative PCR (qPCR) using standard TaqMan
assay conditions and large T primers (TaqMan, Thermo Fisher Scientiﬁc,
Waltham, MA) as previously described [14]. Each sample was run in tripli-
cate on an ABI 7300 Real-time PCR System (Thermo Fisher, Waltham, MA).
JCV DNA viral load in PBMC were expressed as copies per mg of DNA used for
qPCR. DNAviral load in plasma and urinewere expressed as copies per mL of
the samples. A sample was considered positive if at least 2 of 3 replicate
wells showed positive ampliﬁcation with a limit of detection of 188 copies
per mL for urine and plasma and 10 copies per mg for PBMC.
Cellular Immune Response to JCV
Intracellular cytokine staining
After 10 to 14 days in culturewith JCV VP1 peptides,1106 lymphocytes
were incubated in RPMI 1640 with 12% FBSmedium, with a vasopeptide VP1
peptide pool (2 mg/mL), or with phorbol 12-myristate 13-acetate (PMA) and
ionomycin (1 mg/mL and 5 mg/mL, respectively) at 37C for 6 hours. After the
ﬁrst hour, all samples receivedmonensin (GolgiStop; BD Bioscience, Franklin
Lakes, NJ). Cells were stained with ﬂuorescently conjugated antibodies
speciﬁc for human CD4 (clone L200) and CD8 (clone SK1), then ﬁxed, per-
meabilized (BD Cytoﬁx/Cytoperm), and stained with antibodies speciﬁc for
IFN-g (clone B27) and CD3 (clone SK7). All antibodies were obtained from
BD Biosciences. Data were acquired on a FACS Calibur ﬂow cytometer (BD
Biosciences) and analyzed with FlowJo software (Treestar, Ashland, OR). The
intracellular cytokine staining (ICS) result was considered positive when the
percentage of IFN-geproducing CD4þ or CD8þ T cells was equal to or greater
than 2 times the baseline value. The ICS results were reported after sub-
traction of baseline value as previously described [12].
ELISpot
In this assay, 1  105 lymphocytes were incubated on 96-well Multi-
Screen HTS plates (Millipore, Billerica, MA) coated with anti-human IFN-g
(5 mg/mL) in RPMI 1640 with 12% FBS medium, with a VP1 peptide pool
(2 mg/mL), or with phytohemagglutinin (10 mg/mL) at 37C overnight. After
washing, the plates were incubated with antihuman IFN-g biotin (U-Cytech,
Utrecht, Netherlands) for 2 hours at room temperature, washed, and incu-
bated with streptavidin (Southern Biotechnology, Birmingham, AL). The
plates were developed with nitroblue tetrazolium-5-bromo-4-chloro-
3-indolylphosphatechromogen (Pierce, Rockford, IL) and analyzed on an
Immunospot Analyzer (Cellular Technology, Shaker Heights, OH). Results
were considered positive when the number of spot forming units was
greater than 50 per 106 cells after subtraction of baseline, and greater than 3
times the baseline value. Results were reported after subtraction of baseline
values.
Tetramer staining
Tetramer stainings were performed in human leukocyte antigen (HLA)-
A*0201-positive study subjects. Lymphocyteswere stimulatedwith theHLA-
A*0201-restricted JCV VP1 epitopes, VP1p36 or VP1p100, and stained with a
ﬂuorescently conjugated tetramer speciﬁc to HLA-A*0201/VP1p36 or HLA-
A*0201/VP1p100 as previously described [15]. Data were acquired on a FACS
Calibur ﬂow cytometer (BD Biosciences) and analyzed with FlowJo software.Humoral Immune Response to JCV
Anti-JCV IgM, IgG, and IgA were quantiﬁed by ELISA as previously
described [16]. All samples were run in duplicate and the mean values are
reported.
Statistical Analysis
Because of the longitudinal nature of the data, which were collected at 4
time intervals of interest (before HSCT and 3 months, 6 months, and 12 to
18 months after HSCT), we ﬁrst used a smoothing cubic spline function to
graphically examine the underlying trend of the dependent variables
(eg, percentages of JCV-speciﬁc CD4þ T lymphocytes) through time.
Potential nonlinear effect of time was visualized especially at the last
time interval. The 4 different categorical study time points were used to
model the time effect. The within-subject correlation in the data was
taken into account in the modeling using linear mixed-effects model.
We used compound symmetry or autoregression as the variance-
covariance structure. We also adjusted for the potential confounders
with the 6 covariates (transplantation type, conditioning regimen, graft-
versus-host disease, presence of concurrent viremia, age, and diagnosis
of acute myelogenous leukemia) in the linear mixed-effects models. We
found that the dependent variables were largely non-normal and the
covariates were mostly statistically nonsigniﬁcant; therefore, we also
used a nonparametric test, Kruskal-Wallis, to assess the effect of time.
The inference on the time effect was similar in both the parametric (with
linear mixed-effects model) and nonparametric analyses. We chose to
report the results from the nonparametric tests. We also used Spearman
correlation coefﬁcients to assess the association between JC viremia,
viruria, and cellular and humoral immune response parameters. We
used the SAS software version 9.12 for all of the analyses.
RESULTS
Subjects Characteristics
We enrolled a total of 30 patients undergoing allogeneic
HSCT at Beth Israel Deaconess Medical Center. Patients were
followed up to 18 months after HSCT. Two patients died in
the initial 100 days after transplantation, and 5 other
patients passed away before reaching the last study time
point. No patient developed PML. Two thirds of these
patients were male and the most frequent indication for
HSCT was acute myelogenous leukemia (Table 1). Although 6
patients had umbilical cord transplantation, others had
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(22 of 30) had myeloablative conditioning. High-resolution
HLA typing was performed on all study subjects. Fourteen
patients were HLA-A*0201 positive, for which we have pre-
viously mapped JCV immune-dominant epitopes. Tetramer
staining assays for these epitopes were performed on sam-
ples from the HLA-A*0201epositive patients. Donor leuko-
cytes were obtained and tested for the presence of JCV DNA
by qPCR. JCV was detected at a quantity below our limit of
detection in only 1 donor sample. The recipient of this
sample did not have any detectable JCV DNA in blood or
urine samples. Eleven patients had evidence of active viral
replication during the course of the study, including 7 with
cytomegalovirus in blood, 3 with Epstein Barr virus (EBV) in
blood, 2 with varicella zoster reactivation in skin, 1 with
human herpes virus 6 in cerebral spinal ﬂuid, and 1 with
parainﬂuenza virus detected from bronchial lavage. Two
patients had both cytomegalovirus and EBV and 1 had both
EBV and varicella zoster.
Decreased Prevalence of JC Viremia after HSCT
Blood and urine samples were collected at 4 differ-
ent time points: before HSCT (median, 27; range, 77
to 6 days); and 3 months (median, 97; range, 100 to
120 days), 6 months (median, 183; range, 121 to 220 days),
and 12 to 18 months (median, 387; range, 221 to 529 days)
after HSCT. Pre-HSCT JCV DNA was detected in 7 of 30 (23%)
urine, 5 of 30 (17%) PBMC, and 6 of 30 (20%) plasma samples
(Table 2). Fifteen (50%) of the 30 study patients had detect-
able JCV DNA in at least 1 sample in either the plasma or in
the PBMC during the time of the study. In plasma, the
number of patients with detectable JCV DNA decreased after
transplantation to 4 (18%) at 3 months, 0 at 6 months, and 1
patient (5%) at 12 to 18 months (DNA viral load mean, 565;
range, 270 to 2900 copies/mL). In PBMC, the detection of JCV
DNA peaked at 19% at 6 months after transplantation and
also decreased at 12 to 18 months (DNA viral load mean, 56;
range, 17 to 250 copies/mg). Although JCV DNA was detected
in plasma and PBMC of different patients in our study, it is
usually not detected in the blood of healthy individuals [17].
Detection of JCV DNA in urine at the 4 study time points
ranged from 23% to 39% (DNA viral load mean, 2.8  107;
range, 200 to 3.2  108 copies/mL), similar to the detection
frequency in healthy individuals [18]. Fourteen (47%) of the
30 patients had at least 1 urine sample positive for JCV DNA
during the study period. Of these, 6 patients (43%) had
detectable JCV DNA in at least 3, if not all 4, study time points.
Detection of JCV DNA in either blood or urine of these pa-
tients was not correlated with any clinical symptom of viral
infection or the diagnosis of graft-versus-host disease, and
did not affect post-transplantation survival in this cohort.Table 2
Prevalence of JCV DNA in Blood and Urine, Anti-JCV Antibodies, and Cellular Immu
Time Point JCV DNA Detection by qPCR Anti-JCV
Serum PBMC Urine IgM
Before Transplantation 6 of 30 (20%) 5 of 30 (17%) 7 of 30 (23%) 2 of 30
3 Mo 4 of 22 (18%) 2 of 22 (9%) 9 of 23 (39%) 1 of 23
6 Mo 0 of 21 4 of 21 (19%) 7 of 19 (37%) 2 of 21
12-18 Mo 1 of 22 (5%) 0 of 22 5 of 21 (24%) 1 of 22
PBMC indicates peripheral blood mononuclear cells; qPCR, quantitative polymeras
immune spot.
Data presented are the number of positives of total numbers tested (%).JCV-speciﬁc Humoral Immune Response Remains Stable
Over Time after HSCT
Although the prevalence of JCV-speciﬁc IgG (IgG)
remained stable from 83% before HSCT to 72% at 12 to
18 months, JCV-speciﬁc IgM (IgM) was rarely detected
(Table 2). Before HSCT, 2 out of 30 patients had detectable
IgM. Although both of these patients had detectable JCV DNA
in their urine at all study time points, only 1 had detectable
JCV DNA in PBMC before HSCT, and neither had detectable
JCV DNA in plasma at any study time point. One patient, who
had detectable JCV DNA in PBMC before HSCT, became IgM
positive at 3 months after transplantation and remained IgM
positive at 6 months after transplantation. There was no
serum available at 12 to 18 months for this patient. One
patient became IgM positive at 6months and another patient
became IgM positive at the 12 to 18-months study point. All
patients who were IgM positive were also IgG positive,
indicating viral reactivation rather than a primary infection.
IgG quantity ﬂuctuated above and below the threshold for
positive response throughout the study period. One patient
remained negative at all 4 time points, despite detectable JCV
DNA in the serum 3 months after transplantation. This is an
example of a detectable JCV infection in a seronegative in-
dividual as reported by others [19]. Four patients with
negative IgG before transplantation became IgG positive in
later study time points. Anti-JCV IgA (IgA) was positive in
1 subject at 3 months and in 2 different subjects at 6 months
after transplantation. Lastly, although there were no statis-
tically signiﬁcant quantitative changes in IgG, IgM, and IgA
levels over the course of the transplantation, the JCV-speciﬁc
antibody response correlated well each other. Spearman
correlation coefﬁcients were signiﬁcantly positive for IgG to
IgM (.29, P ¼ .004), IgG to IgA (.26, P ¼ .01), IgA to IgM (.42,
P ¼ < .0001).
JCV-speciﬁc Cellular Immune Response Increases Over
Time after HSCT
Qualitative analysis showed JCV-speciﬁc cellular immune
response peaked at 12 to 18 months in both CD4þ T cells and
CD8þ T cells, as well, as by ELISpot (Table 2). We analyzed the
exact date of each sample collection and the percentage of
IFN-geproducing CD4þ and CD8þ T cells by ICS. The
nonlinear curve showed the quantitative increased per-
centage of JCV-speciﬁc CD4þ and CD8þ T cells over time
(Figure 1).
We next grouped the samples according to the 4 study
time points: before HSCT, and 3, 6, and 12 to 18 months after.
The linear mixed-effects model with the 4 time points and
6 covariates showed the adjusted effect of time to be statis-
tically signiﬁcant (P ¼ .012). Because of the small sample size
of subjects with cellular or humoral immune response abovene Responses
Antibodies Cellular Immune Responses
ICS ELISpot
IgG CD4þ CD8þ
(7%) 25 of 30 (83%) 15 of 23 (65%) 14 of 23 (61%) 12 of 19 (63%)
(4%) 19 of 23 (83%) 12 of 15 (80%) 6 of 15 (40%) 10 of 13 (77%)
(10%) 15 of 21 (71%) 13 of 20 (65%) 13 of 20 (65%) 3 of 5 (60%)
(5%) 16 of 22 (73%) 22 of 23 (96%) 17 of 23 (74%) 14 of 15 (93%)
e chain reaction; ICS, intracellular cytokine staining; ELISpot, enzyme-linked
Figure 1. Increase of JCV-speciﬁc CD4þ and CD8þ T cells over time after
transplantation. The percentages of (A) JC virus-speciﬁc CD4þ and (B) CD8þ
T cells increased after hematopoietic stem cell transplantation.
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immune response were highly non-normal. Small sample
size also prevented us from having sufﬁcient statistical po-
wer to assess the normality assumption using the Shapiro-
Wilk test. Therefore, we used the nonparametric Wilcoxon
rank-sum test to compare the distributions of these immune
response variables. Because of the non-normality in the
distribution of the dependent variable JCV-speciﬁc CD4þ and
CD8þ T cells, and the nonsigniﬁcance of 4 of the 6 covariates,
we also estimated the signiﬁcance of the time effect using
the nonparametric Kruskal-Wallis test, which yielded a
P value of .004 for CD4þ T cells (Table 3, A).
We examined the distribution of age as a continuous
variable relative to the immune response variables and found
that age had potentially a nonlinear association with these
variables; therefore, we decided to categorize age into
quartiles to capture the nonlinear effect. Table 3, A results
showed the signiﬁcant effect of age, which could also be
colinear with the time effect. The diagnosis of acute mye-
logenous leukemia was also found to have signiﬁcant nega-
tive effect on percentage of JCV-speciﬁc CD4þ T cells (P <
.0001). Interestingly, in this cohort, at the 12 to 18-months
study time point, the percentage of JCV-speciﬁc CD4þ
T cells was signiﬁcantly higher than that in healthy controls
(P ¼ .0087). Conversely for JCV-speciﬁc CD8þ T cells (Table 3,
B), we found no signiﬁcant effect of time; although, themean
estimates showed an increasing trend at 6 months and 12 to
18 months after HSCT, compared with before HSCT and
3 months after HSCT. Furthermore, the effect of age did not
reach signiﬁcance in JCV-speciﬁc CD8þ T cells. As in JCV-
speciﬁc CD4þ T cells, we also found that the diagnosis of
acute myelogenous leukemia had a negative effect on
the mean percentage of JCV-speciﬁc CD8þ T cells (P ¼ .003).The transplantation type, conditioning regimen, presence of
graft-versus-host disease, and concurrent viremia from other
viruses had no signiﬁcant inﬂuence on the CD4þ or CD8þ
T cell responses.
Tetramer staining for the previously mapped HLA A*0201
JCV-speciﬁc dominant epitopes VP1p36 and - p100 were per-
formed on the blood samples of 14 HLA A*0201-positive
patients. The results correlated to the presence of JCV-
speciﬁc CD8þ T cells on ICS performed at the same time
point (data not shown).
JC Viremia Correlated with Selective Increase in Cellular
Immune Response
Weperformed stratiﬁed analysis based on the presence or
absence of JC viremia. We divided the patients into 2 groups
(viremia [n ¼ 15] versus no viremia [n ¼ 15]), based on at
least 1 detection of JCV in either PBMC or serum, and we
analyzed their cellular immune responses at the 4 study time
points (Figure 2). For comparison purposes, we included a
previously published healthy control group [12]. Overall,
both ICS and ELISpot showed similar levels of JCV-speciﬁc
cellular immune responses between the JC viremia and the
no viremia groups at all study time points. The frequency of
JCV-speciﬁc CD4þ T cells was signiﬁcantly higher in the JC
viremia group at 12 to 18 months compared with 6 months
of the same group (P ¼ .045). Also, the JC viremia group 12 to
18 months after transplantation had signiﬁcantly more JCV-
speciﬁc CD4þ T cells than those in the healthy control
group (P ¼ .021). Conversely, JCV-speciﬁc CD8þ T cell
responses were signiﬁcantly higher at 12 to 18 months,
comparedwith 3months, in the no JC viremia group (P¼ .026).
ELISpot demonstrated signiﬁcantly stronger cellular immune
response in the no viremia group before transplantation as
compared with the viremia group (P ¼ .024).
Although ICS separately assays CD4þ and CD8þ T cell
responses, ELISpot measures both responses together. JCV-
speciﬁc T cell responses by ELISpot correlated well to both
JCV-speciﬁc CD4þ and CD8þ T cell responses by ICS with
Spearman correlation coefﬁcients of .62 (P < .0001) and .33
(P ¼ .04), respectively. ICS CD4 results also correlated well to
ICS CD8 results (.28, P ¼ .01).
Correlations of JCV Viruria, Viremia, and Immune
Responses
We next correlated the presence of JCV DNA in serum,
PBMC, and urine to JCV-speciﬁc humoral and cellular im-
mune responses. We detected signiﬁcant positive correla-
tions between JCV DNA load in the urine and the amount of
IgG in the blood on all samples (Spearman coefﬁcient ¼ .46,
P  .0001). Based on this ﬁnding, we further analyzed the 6
patients with JC viruria in at least 3 of 4 study time points.
Compared with all other study patients, these patients had
IgG levels that were signiﬁcantly elevated before trans-
plantation and at 3 months and 12 to 18 months afterwards
(Figure 3). JCV DNA load in urine samples also correlated to
the amount of IgA (Spearman coefﬁcient ¼ .24, P ¼ .026).
These data showed a strong association between JCV in the
urine and elevated anti-JCV immunoglobulins, suggesting
that JCV reactivation in the kidneys can trigger JCV-speciﬁc
humoral immune response.
In blood, we detected nonsigniﬁcant correlations. The JCV
DNA load in plasma negatively correlated with T cell re-
sponses measured by ELISpot (Spearman coefﬁcient ¼ .22,
P ¼ .12), and the JCV DNA load in PBMC also negatively
correlated to JCV-speciﬁc CD4þ T cells as measured by ICS
Table 3
Evolution of the Cellular Immune Response to JC Virus after HSCT
A. JCV-Speciﬁc CD4þ T cells Number of Subjects % IFN-gþCD4þ T Cells (Unadjusted Mean  std dev) Median (Range) P (Kruskal-Wallis)
Time from transplantation
Before transplantation 23 .55  .96 0 (0-5.44)
3 mo 15 .89  1.60 .04 (0-7.83)
6 mo 20 1.01  2.34 0 (0-13.43)
12-18 mo 23 2.91  7.40 .31 (0-44.12) .0041
Transplantation type
Cord 6 1.02  1.95 0 (0-8.21)
MUD 13 1.46  3.28 .03 (0-26.17)
MRD 11 1.48  6.02 .03 (0-44.12) .54
Conditioning
MC 22 1.00  1.86 .06 (0-9.32)
RIC 8 1.55  4.90 0 (0-44.12) .26
Graft-versus-host disease
No 19 1.78  5.13 0 (0-44.12)
Yes 11 .88  2.71 .07 (0-26.17) .76
Concurrent viremia
No 19 1.57  5.14 .02 (0-44.12)
Yes 11 1.18  2.83 0 (0-26.17) .86
Age, yr
<49 8 .62  1.14 .01 (0-5.47)
49-58 8 2.48  4.16 .68 (0-26.17)
59-63 10 1.57  6.20 0 (0-44.12)
>63 4 .53  .94 0 (0-3.84) .0012
Diagnosis of AML
No 17 1.61  3.04 .41 (0-26.17)
Yes 13 1.15  5.43 0 (0-44.12) <.0001
B. JCV-Speciﬁc CD8þ T cells Number of Subjects % IFN-gþCD8þ T Cells (Unadjusted Mean  std dev) Median (Range) P (Kruskal-Wallis)
Time from transplantation
Before transplantation 23 .16  .45 0 (0-3.26)
3 mo 15 .06  .21 0 (0-1.40)
6 mo 20 .25  .65 0 (0-4.32)
12-18 mo 23 1.12  4.82 0 (0-33.96) .11
Transplantation type
Cord 6 .7  3.14 0 (0-21.29)
MUD 13 .54  3.25 0 (0-33.96)
MRD 11 .18  .57 0 (0-4.32) .83
Conditioning
MC 22 .77  3.41 0 (0-23.52)
RIC 8 .31  2.27 0 (0-33.96) .18
Graft-versus-host disease
No 19 .39  2.56 0 (0-33.96)
Yes 11 .50  2.74 0 (0-23.52) .90
Concurrent viremia
No 19 .52  3.09 0 (0-33.96)
Yes 11 .33  1.86 0 (0-21.29) .09
Age, yr
<49 8 .36  2.11 0 (0-21.29)
49-58 8 1.13  4.65 0 (0-33.96)
59-63 10 .1  .28 0 (0-1.76)
>63 4 .08  .16 0 (0-.67) .08
Diagnosis of AML
No 17 .64  3.18 0 (0-33.96)
Yes 13 .2  1.75 0 (0-21.29) .003
HSCT indicates hematopoietic stem cell transplantation; cord, umbilical cord blood transplantation; MUD, matched unrelated donor; MRD, matched related
donor; MC, myeloablative conditioning; RIC, reduced-intensity conditioning; AML, acute myelogenous leukemia.
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that a weaker cellular immune response to JCV may be
associated with the presences of JCV DNA in PBMC and
plasma, which suggest that loss of JCV-speciﬁc cellular im-
mune controls may result in JCV reactivation in blood.
We examined the relationships between humoral and
cellular immune responses. Although IgA and IgM did not
have signiﬁcant correlations with T cell responses, IgG
consistently inversely correlated with all T cell responses
with ELISpot (Spearman coefﬁcient ¼ .42, P ¼ .0019), with
ICS CD4þ T cells (Spearman coefﬁcient ¼ .20, P ¼ .077), and
with ICS CD8þ T cells (Spearman coefﬁcient ¼ .16, P ¼ .14).DISCUSSION
This prospective study examines JC viral reactivation and
the consequent host immune responses in a cohort of HSCT
subjects. Following the same individual from before trans-
plantation through at least 1 year after transplantation
allowed us to analyze the progression of viral and host in-
teractions in a maturing immune system. This provides an
opportunity to observe JCV immune response in the initially
immunosuppressed state and the dynamic progression to
the restoration of immune system. In this study, we found
that JCV does reactivate and the prevalence of JC viremia in
patients undergoing HSCT was higher than in healthy
Figure 2. Differences in JCV-speciﬁc CD4þ and CD8þ T cells responses in patients with or without viremia. (A) JCV-speciﬁc CD4þ T cells signiﬁcantly increased in the
JC viremic subgroup at 12 to 18 months as compared with the same group at 6 months after transplantation. (B) JCV-speciﬁc CD8þ T cells in the no JC viremia group at
12 to 18 months was higher than the same group at 3 months after transplantation. (C) ELISpot demonstrated a signiﬁcantly elevated T cell response in the subgroup
without JCV viremia at the pretransplantation time point as compared with those with JCV viremia.
Figure 3. Humoral immune response to JCV increase in patients with three
or more JCV DNA positive urine samples. Quantitatively higher levels of anti
JCV-IgG were detected in the subgroup with 3 or more JCV positive urine
samples at the pretransplantation, and 3 and 12 months after transplantation
study time points. Dashed line: cut-off for positive values (OD405nm ¼ .15).
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of the general population. Although the cellular immune
responses to JCV were activated after bone marrow recon-
stitution, the transplanted adaptive immune system could
not fully respond to JCV reactivation until 1 year after
transplantation. Although JCV reactivates independently in
plasma, PBMC, and urine compartments, the presence of JCV
in urine appeared to trigger a humoral immune response,
and the development of JC viremia may be caused by a
decrease in cellular immune response.
JCV Reactivation in Blood and Urine of HSCT Patients
The prevalence of JCV DNA in the blood of our cohort up to
6 months after bone marrow transplantation is similar to
those described for HIV-positive individuals without PML
[17]. Because JC viremia is usually not present in healthy
individuals, the detection of JC viremia in HSCT patients in
our study may indicate an increased risk of central nervous
system seeding by JCV during systemic immunosuppression.
Unlike in HIV-positive individuals with AIDS, where immu-
nosuppression generally lasts years, host immune responses
in HSCT patients are most often restored within approxi-
mately 1 year after transplantation, shortening the total
duration of immunosuppression and the consequent expo-
sure of JCV. Therefore, the decreased exposure time to JC
viremia may explain why fewer HSCT patients develop PML
as compared with HIV-positive individuals with AIDS.
It is unclear whether JCV exists in the blood as a cell-free
or cell-associated virus, and whether it is attached to the cell
surface or carried intracellularly. Therefore, we separately
analyzed JCV detection in the serum and the PBMC samples,
which showed that these constitute distinct and indepen-
dent sites of viral latency and may be governed by different
mechanisms of reactivation.
The decrease of JC viral load in blood was not observed in
urine. Similar to prior studies, we also did not ﬁnd anycorrelation between JCV reactivation in urine and in the
blood compartments [17,20]. This suggests that JCV reac-
tivation from latency in the kidneys tubular epithelial cells
and bone marrow are independent.JC Viremia and Viruria Correlate with Immune Responses
This is the ﬁrst study to follow a cohort of patients pro-
spectively and analyze the detection of JCV in both the urine
and the blood compartments and to correlate them to both
host humoral and cellular immune responses. In the pre-
transplantation study time point, study subjects with no JC
viremia had signiﬁcantly higher JCV-speciﬁc CD4þ and CD8þ
T cell responses than those with JC viremia, as measured by
ELISpot. These results suggest that hosts with a more efﬁ-
cient immune system can control JCV reactivation in blood.
Furthermore, JCV detection is curtailed in both serum and
PBMC in hosts with better overall immune responses,
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mune responses as detected by ICS at 12 to 18-months study
time point, where patients with JC viremia had signiﬁcantly
higher JCV-speciﬁc CD4þ T cell response than those detected
in healthy controls, who do not have detectable JCV DNA in
blood. However, despite the above differences in cellular
immune responses by the JC viremic group, the majority of
the time, patients with JC viremia did not have signiﬁcantly
different levels of cellular immune responses than patients
without viremia. This may be caused by the small sample
size of our study. Alternatively, this may also indicate that
although HSCT restores host immune responses, the cellular
immune response, especially CD8þ T cells, is less effective
than in healthy individuals. In addition, the lack of IFN-g
expression on CD4þ or CD8þ Tcells in those patients with JCV
viremia may reﬂect a Th2 response [21]. Future studies
analyzing IL-10 and other Th2 cytokines response in these
patients will expand our understanding of JCV-speciﬁc
cellular immune responses.
Although the detection of JCV DNA in the urine remained
relatively constant throughout the course of bone marrow
transplantation, the JC viral load in urine correlated directly
with the quantity of both IgG and IgA. Study subjects with
JCV in at least 3 urine samples had signiﬁcantly higher
quantities of IgG than those with fewer urine samples posi-
tive for JCV at 3 out of 4 study time pointsdindicating that
JCV activity in the kidney may trigger the humoral immune
response. Furthermore, the humoral immune responses
were not inﬂuenced by JC viremia, indicating that these re-
sponses were not able to control and stop JC viral replication.
Clinical Factors Associated with JCV-speciﬁc Cellular
Immune Response
We have attempted to identify risk factors that signiﬁ-
cantly inﬂuence JCV-speciﬁc cellular immune response in
this cohort of study subjects. Our data demonstrate that both
CD4þ and CD8þ T cell responses dramatically increase with
time from transplantation. Furthermore, the recovery of
CD4þ T cell responses to JCV occurs earlier and is stronger
than those of CD8þ Tcells. Age, as separated into the 4 groups
in our study, was identiﬁed as a signiﬁcant factor, with those
younger than 49 years and those older than 63 years having a
lower CD4þ T cellemediated cellular immune response to
JCV. This could be because patients in these 2 groups un-
dergoing HSCT may have serious malignancies with immune
dysfunction, even after transplantation. In addition, immune
senescence may also play a role in the low cellular immune
responses to JCV in the older age group. Lastly, those patients
with acute myelogenous leukemia have difﬁculties gener-
ating JCV-speciﬁc cellular immune responses, indicating the
severe immunosuppression associated with this disease.
Correlations between Humoral and Cellular Immune
Responses
This is the ﬁrst study to measure both cellular and hu-
moral immune responses against JCV at the same time
points, allowing for analysis of correlations between these 2
arms of the immune responses. We used both ICS and ELI-
Spot assays for detection of JCV-speciﬁc cellular immune
responses. Although the strong correlations of the data ob-
tained from both assays indicate consistency and reproduc-
ibility of our data, each assay also provided unique insights to
the dynamic changes of JCV-speciﬁc cellular immune
response in the course of HSCT. The JCV-speciﬁc cellular im-
mune response, as tested by both ICS and ELISpot, correlatednegatively with anti-JCV IgG. This suggests that the cellular
immune response is able to control JCV replication and,
consequently, decrease the overall antigenic stimulation,
resulting in the associated decrease in production of IgG.
Future Studies
The consecutive enrollment of patients who present for
bone marrow transplantation allows for a realistic repre-
sentation of the at-risk population. However, the design
includes heterogeneity in the study population. Our cohort of
patients had different types of hematologic malignancies,
bone marrow sources, and conditioning regimens. Although
we attempted to correlate host immune responses to the
presences of JCV DNA in the same study time point, the
expanse of our 4 study time points did not allow for exam-
ination of time lag inﬂuences of viral reactivation on immune
responses. In addition, although use of steroids and other
immunosuppressants can contribute to host immune re-
sponses, our cohort was too small to examine this question.
Future studies examining JCV-speciﬁc immune responses in
a more homogenous population with closer time points may
offer further insights to factors that are associated with
robust responses. Furthermore, the total T cell counts or the
amount of IgG in each patient was not examined in this study
because we chose to focus on the speciﬁc anti-JCV functions
of both B and Tcells. Future studies examining total IgG levels
and T cell counts, along with functional studies, will help us
understand better the kinetics of immune responses after
transplantation.
CONCLUSIONS
In this prospective study in HSCT patients, we detected
JCV viral reactivations in blood and urine, analyzed JCV-
speciﬁc humoral and cellular immune responses, and
correlated the ﬁndings. Our data demonstrated that JC
viremia is prevalent in HSCT patients even before trans-
plantation and does not curtail until 12 to 18 months after
transplantation. Furthermore, although the humoral im-
mune responses are linked to the presence of JCV in urine,
these responses cannot control viral replications in blood or
urine. In addition, the cellular immune responses were not
fully developed until close to 1 year after transplantation.
Therefore, HSCT patients are at increased risk for JC viral
dissemination to the brain and development of PML, espe-
cially those with acute myelogenous leukemia and those in
the older and younger age groups.
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